Soleus Capital Management, L.P.
GREENWICH, CT
$2.9bn in 97 US stocks at the end of 30 June 2026. The top 10 are 48.9% of the money. It changed about 25.5% of the portfolio this quarter.
Value
$2.9bn
Stocks
97
Top 10 share
48.9%
Turnover
25.5%
What changed this quarter
New
Bought for the first time this quarter.
- ErascaERAS1.7% of the fund
- Parabilis MedicinesPBLS1.4% of the fund
- Legend BiotechLEGN1.2% of the fund
- UnitedHealth GroupUNH1.1% of the fund
- Palisade BIOPALI0.9% of the fund
- Supernus PharmaceuticalsSUPN0.8% of the fund
- Nuvectis PharmaNVCT0.6% of the fund
- Capricor TherapeuticsCAPR0.6% of the fund
- Prelude TherapeuticsPRLD0.6% of the fund
- Avalyn PharmaAVLN0.5% of the fund
- Spyre TherapeuticsSYRE0.4% of the fund
- Nektar TherapeuticsNKTR0.3% of the fund
- ArtivionAORT0.3% of the fund
- Belite BIOBLTE0.3% of the fund
- Silence TherapeuticsSLN0.2% of the fund
- ImmunicIMUX0.2% of the fund
- Adlai NortyeANL0.2% of the fund
- Zentalis PharmaceuticalsZNTL0.2% of the fund
- ArriVent BioPharmaAVBP<0.1% of the fund
- Solid BiosciencesSLDB<0.1% of the fund
- GeneDx HoldingsWGS<0.1% of the fund
- EquilliumEQ<0.1% of the fund
Added
Bought more of a stock they already held.
- CelcuityCELC6.1% of the fund+33%
- InsuletPODD5.5% of the fund+86%
- United TherapeuticsUTHR4.2% of the fund+21%
- Inspire Medical SystemsINSP3.0% of the fund+235%
- Rigel PharmaceuticalsRIGL2.5% of the fund+18335%
- ANI PharmaceuticalsANIP2.5% of the fund+6%
- GeronGERN1.9% of the fund+3%
- Arcus BiosciencesRCUS1.2% of the fund+159%
- Nurix TherapeuticsNRIX1.2% of the fund+56%
- Jade BiosciencesJBIO1.2% of the fund+95%
- Avalo TherapeuticsAVTX1.1% of the fund+274%
- UroGen PharmaURGN1.1% of the fund+14%
- MBX BiosciencesMBX1.0% of the fund+188%
- PharvarisPHVS0.9% of the fund+4%
- PROCEPT BioRoboticsPRCT0.8% of the fund+527%
- Tango TherapeuticsTNGX0.8% of the fund+58%
- Argenx SEARGX0.6% of the fund+470%
- OrthopediatricsKIDS0.5% of the fund+19%
- BiodesixBDSX0.5% of the fund+41%
- ImmunovantIMVT0.3% of the fund+10%
- InsmedINSM0.3% of the fund+780%
- Structure TherapeuticsGPCR0.2% of the fund+34%
Cut
Sold some of their stake.
- Krystal BiotechKRYS12.0% of the fund-19%
- TG TherapeuticsTGTX5.5% of the fund-27%
- NovoCureNVCR5.2% of the fund-6%
- VericelVCEL2.2% of the fund-43%
- Praxis Precision MedicinesPRAX2.0% of the fund-46%
- Alkermes plc.ALKS1.9% of the fund-48%
- ProgynyPGNY1.6% of the fund-23%
- Indivior PharmaceuticalsINDV1.5% of the fund-16%
- Globus MedicalGMED1.3% of the fund-36%
- Syndax PharmaceuticalsSNDX1.2% of the fund-6%
- Trevi TherapeuticsTRVI0.8% of the fund-27%
- Biomarin PharmaceuticalBMRN0.7% of the fund-42%
- LivaNovaLIVN0.7% of the fund-56%
- Edgewise TherapeuticsEWTX0.6% of the fund-69%
- Xenon PharmaceuticalsXENE0.6% of the fund-9%
- C4 TherapeuticsCCCC0.5% of the fund-11%
- Kiniksa Pharmaceuticals InternationalKNSA0.5% of the fund-53%
- Twist BioscienceTWST0.4% of the fund-91%
- Vir BiotechnologyVIR0.4% of the fund-50%
- Alnylam PharmaceuticalsALNY0.3% of the fund-75%
- SOPHiA GENETICS SASOPH0.3% of the fund-15%
- Mirum PharmaceuticalsMIRM0.3% of the fund-81%
- Tandem Diabetes CareTNDM0.3% of the fund-27%
- Enliven TherapeuticsELVN0.3% of the fund-28%
- Sionna TherapeuticsSION0.3% of the fund-39%
Sold out
Sold their entire stake.
- VaxcytePCVX-100%
- IconICLR-100%
- Travere TherapeuticsTVTX-100%
- Inhibrx BiosciencesINBX-100%
- DexcomDXCM-100%
- ImmunicIMUX-100%
- Eton PharmaceuticalsETON-100%
- Arrowhead PharmaceuticalsARWR-100%
- CytomX TherapeuticsCTMX-100%
- Cogent BiosciencesCOGT-100%
- Tyra BiosciencesTYRA-100%
- Staar SurgicalSTAA-100%
- AnaptysbioANAB-100%
- Rapport TherapeuticsRAPP-100%
- ZymeworksZYME-100%
- LB PharmaceuticalsLBRX-100%
- Oruka TherapeuticsORKA-100%
- Jasper TherapeuticsJSPR-100%
Holdings
- Parabilis MedicinesPBLS
- Share
- 1.4%
- Value
- $40m
- Shares
- 1,465,070
New
- Edap TMS S AFOCL
- Share
- 1.3%
- Value
- $38m
- Shares
- 7,309,254
Held
- Legend BiotechLEGN
- Share
- 1.2%
- Value
- $35m
- Shares
- 1,205,000
New
- Argenx SEARGX
- Share
- 0.6%
- Value
- $19m
- Shares
- 19,955
+470%
- Avalyn PharmaAVLN
- Share
- 0.5%
- Value
- $14m
- Shares
- 419,000
New
- Belite BIOBLTE
- Share
- 0.3%
- Value
- $8m
- Shares
- 50,524
New
- Structure TherapeuticsGPCR
- Share
- 0.2%
- Value
- $6m
- Shares
- 107,000
+34%
- Adlai NortyeANL
- Share
- 0.2%
- Value
- $5m
- Shares
- 405,523
New
- Satellos BioscienceMSLE
- Share
- <0.1%
- Value
- $2m
- Shares
- 314,359
-24%
- Quoin PharmaceuticalsQNRX
- Share
- <0.1%
- Value
- $352,013
- Shares
- 72,730
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Krystal BiotechKRYS | 12.0% | $349m | 939,254 | -19% |
| CelcuityCELC | 6.1% | $178m | 1,704,318 | +33% |
| TG TherapeuticsTGTX | 5.5% | $161m | 2,927,895 | -27% |
| InsuletPODD | 5.5% | $160m | 1,049,000 | +86% |
| NovoCureNVCR | 5.2% | $150m | 9,913,401 | -6% |
| United TherapeuticsUTHR | 4.2% | $122m | 225,587 | +21% |
| Inspire Medical SystemsINSP | 3.0% | $86m | 1,931,436 | +235% |
| Rigel PharmaceuticalsRIGL | 2.5% | $72m | 1,843,504 | +18335% |
| ANI PharmaceuticalsANIP | 2.5% | $72m | 867,760 | +6% |
| Beta BionicsBBNX | 2.4% | $69m | 4,393,714 | Held |
| VericelVCEL | 2.2% | $65m | 1,459,152 | -43% |
| Praxis Precision MedicinesPRAX | 2.0% | $59m | 177,517 | -46% |
| GeronGERN | 1.9% | $55m | 42,808,659 | +3% |
| Alkermes plc.ALKS | 1.9% | $54m | 1,029,252 | -48% |
| ErascaERAS | 1.7% | $49m | 2,700,000 | New |
| NeuroPaceNPCE | 1.6% | $46m | 2,911,122 | Held |
| ProgynyPGNY | 1.6% | $46m | 1,602,000 | -23% |
| Indivior PharmaceuticalsINDV | 1.5% | $44m | 1,064,000 | -16% |
| Parabilis MedicinesPBLS | 1.4% | $40m | 1,465,070 | New |
| Edap TMS S AFOCL | 1.3% | $38m | 7,309,254 | Held |
| Globus MedicalGMED | 1.3% | $37m | 468,922 | -36% |
| Arcus BiosciencesRCUS | 1.2% | $36m | 1,168,738 | +159% |
| Syndax PharmaceuticalsSNDX | 1.2% | $36m | 1,628,039 | -6% |
| Nurix TherapeuticsNRIX | 1.2% | $36m | 1,465,163 | +56% |
| Legend BiotechLEGN | 1.2% | $35m | 1,205,000 | New |
| Jade BiosciencesJBIO | 1.2% | $34m | 1,550,690 | +95% |
| UnitedHealth GroupUNH | 1.1% | $33m | 80,000 | New |
| Avalo TherapeuticsAVTX | 1.1% | $31m | 1,654,978 | +274% |
| UroGen PharmaURGN | 1.1% | $31m | 829,810 | +14% |
| MBX BiosciencesMBX | 1.0% | $28m | 515,279 | +188% |
| Palisade BIOPALI | 0.9% | $27m | 13,063,687 | New |
| PharvarisPHVS | 0.9% | $25m | 730,907 | +4% |
| Organogenesis HoldingsORGO | 0.8% | $25m | 10,140,951 | Held |
| Supernus PharmaceuticalsSUPN | 0.8% | $24m | 520,000 | New |
| PROCEPT BioRoboticsPRCT | 0.8% | $23m | 1,003,000 | +527% |
| Tango TherapeuticsTNGX | 0.8% | $22m | 709,000 | +58% |
| Inhibikase TherapeuticsIKT | 0.8% | $22m | 10,875,000 | Held |
| Trevi TherapeuticsTRVI | 0.8% | $22m | 1,179,618 | -27% |
| Biomarin PharmaceuticalBMRN | 0.7% | $21m | 375,572 | -42% |
| LivaNovaLIVN | 0.7% | $21m | 254,957 | -56% |
| Argenx SEARGX | 0.6% | $19m | 19,955 | +470% |
| Nuvectis PharmaNVCT | 0.6% | $18m | 1,000,000 | New |
| Capricor TherapeuticsCAPR | 0.6% | $18m | 761,737 | New |
| Edgewise TherapeuticsEWTX | 0.6% | $18m | 450,889 | -69% |
| Prelude TherapeuticsPRLD | 0.6% | $18m | 3,378,378 | New |
| Xenon PharmaceuticalsXENE | 0.6% | $16m | 267,000 | -9% |
| C4 TherapeuticsCCCC | 0.5% | $16m | 3,377,981 | -11% |
| Kiniksa Pharmaceuticals InternationalKNSA | 0.5% | $16m | 246,353 | -53% |
| OrthopediatricsKIDS | 0.5% | $14m | 732,144 | +19% |
| Avalyn PharmaAVLN | 0.5% | $14m | 419,000 | New |
| BiodesixBDSX | 0.5% | $13m | 585,958 | +41% |
| Spyre TherapeuticsSYRE | 0.4% | $13m | 147,000 | New |
| Twist BioscienceTWST | 0.4% | $11m | 104,629 | -91% |
| Vir BiotechnologyVIR | 0.4% | $10m | 1,000,000 | -50% |
| Alnylam PharmaceuticalsALNY | 0.3% | $10m | 33,050 | -75% |
| ImmunovantIMVT | 0.3% | $10m | 252,000 | +10% |
| InsmedINSM | 0.3% | $10m | 90,250 | +780% |
| SepternaSEPN | 0.3% | $9m | 275,000 | Held |
| SOPHiA GENETICS SASOPH | 0.3% | $9m | 1,565,000 | -15% |
| Nektar TherapeuticsNKTR | 0.3% | $9m | 128,362 | New |
| Mirum PharmaceuticalsMIRM | 0.3% | $9m | 75,000 | -81% |
| ArtivionAORT | 0.3% | $9m | 388,000 | New |
| Tandem Diabetes CareTNDM | 0.3% | $9m | 575,000 | -27% |
| Enliven TherapeuticsELVN | 0.3% | $8m | 165,677 | -28% |
| Sionna TherapeuticsSION | 0.3% | $8m | 177,687 | -39% |
| Belite BIOBLTE | 0.3% | $8m | 50,524 | New |
| CerusCERS | 0.3% | $7m | 2,500,000 | -77% |
| Silence TherapeuticsSLN | 0.2% | $7m | 630,000 | New |
| ImmunicIMUX | 0.2% | $7m | 450,000 | New |
| InvivydIVVD | 0.2% | $7m | 7,708,727 | Held |
| MerckMRK | 0.2% | $6m | 50,000 | -75% |
| Relmada TherapeuticsRLMD | 0.2% | $6m | 842,106 | Held |
| Structure TherapeuticsGPCR | 0.2% | $6m | 107,000 | +34% |
| EvolusEOLS | 0.2% | $6m | 822,428 | -63% |
| Adlai NortyeANL | 0.2% | $5m | 405,523 | New |
| Zentalis PharmaceuticalsZNTL | 0.2% | $5m | 950,000 | New |
| Karyopharm TherapeuticsKPTI | 0.1% | $4m | 440,000 | Held |
| Context TherapeuticsCNTX | 0.1% | $4m | 7,063,141 | Held |
| PulmonxLUNG | 0.1% | $4m | 2,788,323 | Held |
| SAB BiotherapeuticsSABS | 0.1% | $4m | 900,000 | -14% |
| Tectonic TherapeuticTECX | 0.1% | $3m | 101,684 | -16% |
| AxogenAXGN | <0.1% | $3m | 57,036 | -92% |
| Satellos BioscienceMSLE | <0.1% | $2m | 314,359 | -24% |
| ArriVent BioPharmaAVBP | <0.1% | $2m | 50,000 | New |
| Corcept TherapeuticsCORT | <0.1% | $2m | 19,653 | -93% |
| Solid BiosciencesSLDB | <0.1% | $1m | 150,000 | New |
| VeracyteVCYT | <0.1% | $1m | 25,000 | -92% |
| Cullinan TherapeuticsCGEM | <0.1% | $910,500 | 50,000 | -88% |
| InspireMDNSPR | <0.1% | $732,100 | 1,045,708 | Held |
| GeneDx HoldingsWGS | <0.1% | $686,500 | 10,000 | New |
| Iovance BiotherapeuticsIOVA | <0.1% | $624,000 | 150,000 | -85% |
| Larimar TherapeuticsLRMR | <0.1% | $573,711 | 188,102 | -82% |
| CG OncologyCGON | <0.1% | $355,250 | 5,000 | -75% |
| Quoin PharmaceuticalsQNRX | <0.1% | $352,013 | 72,730 | Held |
| EquilliumEQ | <0.1% | $288,000 | 90,000 | New |
| NateraNTRA | <0.1% | $271,450 | 1,000 | -99% |
| NeogenomicsNEO | <0.1% | $145,900 | 10,000 | -94% |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 100.4% since 30 June 2025.
Where the money is
Health care95.9%
Technology0.3%
Industrials0.0%
Other3.8%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.